Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · Real-Time Price · USD

5.98

+0.45 (8.14%)

At close: Aug 4, 2026, 4:00 PM EDT

6.00

+0.02 (0.33%)

Pre-market: Aug 5, 2026, 7:41 AM EDT

Aclaris Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	28.66	19.96	24.57	39.88	45.28	27.35
Short-Term Investments	76.76	70.79	89.02	79.23	172.29	164.07
Cash & Short-Term Investments	105.42	90.75	113.59	119.11	217.57	191.41
Cash Growth	0.10%	-20.11%	-4.63%	-45.26%	13.66%	253.61%
Accounts Receivable	4.81	5.57	12.36	0.3	0.48	0.62
Other Current Assets	-	-	-	9.45	13.5	13
Total Current Assets	110.23	96.32	125.95	128.86	231.55	205.03
Net Property, Plant & Equipment	0.75	0.76	1.01	1.62	1.1	1.34
Other Intangible Assets	-	-	-	-	6.97	7.05
Long-Term Investments	85.37	60.61	90.3	62.77	12.24	34.24
Other Long-Term Assets	2.37	2.77	3.07	4.16	2.73	3.55
Total Assets	198.72	160.46	220.33	197.41	254.6	251.21

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	14.73	13.16	4.69	8.88	10.35	9.99
Accrued Expenses	5.9	8.79	20.33	19.45	8.7	10.05
Current Portion of Leases	-	-	-	-	0.68	0.69
Unearned Revenue	3.97	3.94	3.89	-	-	-
Other Current Liabilities	2.77	2.75	2.68	2.63	2.2	2.2
Total Current Liabilities	27.37	28.65	31.6	30.95	21.94	22.93
Other Long-Term Liabilities	27.7	28.73	33.18	9.27	35.04	30.94
Total Long-Term Liabilities	27.7	28.73	33.18	9.27	35.04	30.94
Total Liabilities	55.07	57.38	64.77	40.23	56.98	53.87

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-in Capital	1,131	1,070	1,058	928.08	880.83	792.97
Accumulated Other Comprehensive Income	0.02	0.61	0.1	-0.11	-0.9	-0.22
Retained Earnings	-987.61	-967.78	-902.86	-770.8	-682.32	-595.41
Shareholders' Equity	143.65	103.08	155.55	157.18	197.62	197.34
Total Liabilities & Equity	198.72	160.46	220.33	197.41	254.6	251.21

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	-	0	0	0	0.68	0.69
Net Cash (Debt)	105.42	90.75	113.59	119.11	216.89	190.72
Net Cash Growth	0.10%	-20.11%	-4.63%	-45.08%	13.72%	344.83%
Net Cash Per Share	0.85	0.74	1.47	1.71	3.33	3.36
Book Value	143.65	103.08	155.55	157.18	197.62	197.34
Book Value Per Share	1.16	0.84	2.01	2.25	3.03	3.48
Tangible Book Value	143.65	103.08	155.55	157.18	190.65	190.29
Tangible Book Value Per Share	1.16	0.84	2.01	2.25	2.92	3.35

SEC Filings: 10-K · 10-Q